Filing Details
enGene Therapeutics Inc. (NASDAQ:ENGN) filed a Form 8-K with the Securities and Exchange Commission on July 16, 2026, disclosing a material event.
8k filedNASDAQ:ENGN
enGene Therapeutics Inc. (ENGN) Reports Material Event to SEC
Filing Details enGene Therapeutics Inc. (NASDAQ:ENGN) filed a Form 8-K with the Securities and Exchange Commission on July 16, 2026, disclosing a material event. Market Context…
Market Context
enGene Therapeutics Inc.'s stock currently trades at $1.92 with a market capitalization of $455.6M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for enGene Therapeutics Inc.'s stock.
All SEC filings for enGene Therapeutics Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ENGN Stock Page
Frequently Asked Questions
Where can I read ENGN's SEC filings?
Browse all filings on our ENGN SEC filings page.
What types of SEC filings does enGene Therapeutics Inc. file?
Public companies like enGene Therapeutics Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.